RXRX stock is down 55% because Q1 2026 revenue fell 56% year-over-year to $6.5 million on lumpy milestone timing — but 8 covering analysts still rate Recursion Pharmaceuticals a Hold with a $7.00 average price target, implying 113% upside from the current $3.27 close. The 4.66% single-session drop on May 7 took shares to a new 30-day low, leaving the stock just $0.47 above its 52-week low of $2.80 and squarely at the centre of the AI-drug-discovery sentiment reset.
This balanced RXRX stock price analysis weighs the milestone-driven revenue weakness against the clinical-readout calendar that includes REC-1245 Phase 1 safety data and REC-4881 Phase 2 polyp reduction in familial adenomatous polyposis (FAP). It also examines why is RXRX stock dropping faster than the AI-biotech basket, what the FDA engagement on REC-4881 actually means for valuation, and where the bullish and bearish analyst opinions on Recursion Pharmaceuticals settle on consensus.
Key Stock Data
| Metric | Value |
|---|---|
| Current Price | $3.27 |
| 52-Week Range | $2.80 – $7.18 |
| Market Cap | ~$1.1B |
| P/E Ratio | N/A (unprofitable) |
| Q1 2026 Revenue | $6.5M (-56% YoY) |
| Analyst Consensus | Hold (3 Buys, 0 Sells) |
| Average Price Target | $7.00 |
| Coverage | 4–8 analysts |
Table of Contents
- Key Stock Data
- Key Takeaways on RXRX
- What Is Recursion Pharmaceuticals (RXRX)?
- Recent RXRX Stock Performance
- Why Is RXRX Down Today?
- RXRX Stock Price Analysis – Valuation
- Bullish and Bearish Analyst Opinions on Recursion Pharmaceuticals
- RXRX Stock Clinical Catalysts and Analyst Targets
- RXRX Stock FAQs
Key Takeaways on RXRX
- Price: RXRX trades at $3.27 — within $0.47 of its 52-week low of $2.80 and 55% below the 52-week high of $7.18.
- Verdict: Hold consensus across 8 analysts with a $7.00 average target; balanced setup suggests accumulate on weakness rather than chase strength.
- Key stat: Q1 2026 revenue dropped 56% to $6.5 million, but operating cash expenses were cut 30%, extending runway.
- Bull case: REC-4881 Phase 2 polyp reduction in FAP earned FDA engagement on a registrational pathway; REC-1245 cleared Phase 1 safety with no dose-limiting toxicities.
- Bear case: Revenue volatility from milestone timing, persistent operating losses, and technical signals downgrading the stock from Hold to Strong Sell on momentum.
What Is Recursion Pharmaceuticals (RXRX)?
Recursion Pharmaceuticals is a Nasdaq-listed clinical-stage TechBio company that combines high-throughput biology with machine learning to industrialise drug discovery. The Salt Lake City–based company built one of the largest proprietary biological-imaging datasets in the industry — billions of cell-level data points generated by its own robotic laboratories — and uses that dataset to train models that nominate, validate, and progress drug candidates into the clinic.
The investment thesis collapses to a single bet: that combining AI inference with wet-lab validation will compress the historical 10-to-15-year drug-development timeline into something measurably shorter and cheaper. Recursion’s collaborations with Roche, Bayer, and Tempus — and its 2024 merger with Exscientia — broadened the platform’s reach in oncology, immunology, and rare disease. The market gives RXRX a roughly $1.1 billion market cap today, sharply down from the post-merger peak. The RXRX stock price reflects a market that is now demanding clinical proof points rather than platform narrative.
Recent RXRX Stock Performance
RXRX closed at $3.27 on May 7, 2026, falling 4.66% from the prior session’s $3.43 close. The stock has now declined in 6 of the last 10 trading days and is down 6.57% over that 10-session window. On May 10 the intraday range was $3.20 to $3.35 with a $3.30 settlement, leaving RXRX up 3.1% from the recent low but still 1.4% under the multi-week range high.
Step back to the 12-month view and the picture sharpens: the 52-week high of $7.18 sits 119% above the current price, while the 52-week low of $2.80 is just $0.47 below. That places RXRX in the bottom decile of its annual range — a clear technical drawdown that has triggered momentum-driven sell signals at multiple chart services. One model has explicitly downgraded RXRX from Hold to Strong Sell candidate on momentum, even as fundamental coverage remains anchored at a Buy on three analyst desks and a Hold on five.
The market-cap context matters. At $1.1B, RXRX is no longer pricing for any of the platform-narrative optionality that lifted shares to the $7+ zone in 2025. What investors are paying for today is essentially the cash, the clinical pipeline, and the residual partnership value — with very little credit assigned to the AI inference engine itself.
For traders watching the tape, the implication is unambiguous: this is a name where the long-term thesis has been disconnected from the short-term price action. Each successive drift below $3.50 has triggered fresh momentum-driven selling, and the lack of obvious near-term catalysts between earnings windows has meant the bid has stayed light. That dynamic tends to overshoot in clinical-stage biotech — the same setup that produced the $7.18 high in 2025 can produce a $2.80 retest in 2026 without any change in the underlying clinical pipeline. The balanced read is to separate the chart from the fundamentals; the fundamentals improved in Q1 on operating discipline, even as the revenue print disappointed.
Why Is RXRX Down Today?
Why is RXRX stock dropping right now? The May 7 single-session decline was a 4.66% move on no obvious news catalyst, suggesting the slide is being driven by a combination of fundamental Q1 read-through, technical positioning, and sector-wide rotation. Four drivers stand out.
1. Q1 2026 revenue fell 56% year-over-year to $6.5 million. Recursion’s revenue model is dominated by partnership milestone payments from Roche, Bayer, and others — and those payments arrive in chunky, irregular blocks. A 56% drop in any single quarter is uncomfortable optically, even when management can credibly point to timing rather than degradation in the underlying collaborations. The market is choosing to read it as the former, which has pressured the stock through May.
2. Momentum signals have flipped negative. The break of the $3.50 area triggered technical sell signals at multiple chart services. With the stock now under $3.30 and approaching the 52-week low at $2.80, algorithmic flow has compounded the fundamental concern.
3. AI-biotech sentiment has cooled. The broader TechBio basket — companies that pitched AI-discovered drugs at peak hype — has re-rated lower in 2026 as the clinical readout cadence has not yet validated the platform premium. RXRX, as one of the largest pure-play names in the category, has absorbed disproportionate flows out.
4. Cash burn vs runway remains an investor focus. Even with operating cash expenses cut 30%, persistent losses on a $6.5M quarterly revenue base raise periodic funding questions. The market wants to see either revenue acceleration or a clinical asset clearly tracking toward registration — and RXRX is currently in a gap between catalysts.
RXRX Stock Price Analysis – Valuation
This RXRX stock price analysis sits at the intersection of platform optionality and clinical-stage biotech valuation. Standard P/E and P/S anchors are not useful for an unprofitable name with milestone-heavy revenue. The relevant framing is the gap between the current $3.27 quote and an $8.00 four-analyst average target (or a $7.00 eight-analyst average) — both of which imply significant upside but neither of which has narrowed.
| Valuation Anchor | RXRX | Implication |
|---|---|---|
| Market Cap | ~$1.1B | Small-cap clinical-stage TechBio |
| Q1 2026 Revenue | $6.5M (-56% YoY) | Lumpy milestone timing, not run-rate |
| Operating Expense Trend | -30% YoY | Runway-extending discipline |
| Average Price Target (8 analysts) | $7.00 | 113% above current $3.27 |
| High Target | $11.00 | Implies platform re-rating |
| Low Target | $3.00 | Below current quote |
| 52-Week Low | $2.80 | $0.47 of downside support |
The balanced read: a $3.27 entry sits within 17% of the most pessimistic analyst target on the street, suggesting much of the bear case is already priced in. The path to the $7.00 average target requires the REC-1245 oncology programme and REC-4881 FAP programme to keep producing clean data into Q3/Q4 readouts. The path to the $11.00 high target requires evidence that the platform itself — not just one or two assets — is producing differentiated clinical candidates at scale.
Bullish and Bearish Analyst Opinions on Recursion Pharmaceuticals
The bullish and bearish analyst opinions on Recursion Pharmaceuticals reflect a textbook clinical-stage biotech split: bulls underwrite the platform and the next two readouts; bears focus on cash burn and revenue volatility. With 3 Buys, 5 Holds, and 0 Sells, the consensus has not collapsed even as the stock has.
| Reasons for the Decline | Reasons the Drop Is Overdone |
|---|---|
| Q1 2026 revenue -56% YoY to $6.5M | $7.00 average target implies 113% upside |
| Persistent operating losses | 30% reduction in cash operating expenses |
| 52-week drawdown >55% from $7.18 high | REC-4881 in FAP earned FDA registrational engagement |
| Technical downgrade from Hold to Strong Sell | REC-1245 cleared Phase 1 safety with no DLTs |
| Cooling AI-biotech sentiment sector-wide | Lowest analyst target ($3.00) is below current $3.27 quote — bear case largely priced |
The bullish camp leans heavily on the FAP readout. Familial adenomatous polyposis is a rare disease with a clear regulatory pathway and an enormous unmet need; if REC-4881’s polyp-reduction data hold up at registrational scale, the asset alone could justify the current market cap. The bearish camp argues that the platform thesis — Recursion’s original equity-story differentiator — is invisible in 2026 numbers, and that without a re-acceleration of partnership revenue the cash runway becomes a 2027 question.
RXRX Stock Clinical Catalysts and Analyst Targets
Analyst targets for RXRX stock span $3.00 to $11.00 — a 267% range that captures the binary nature of clinical-stage biotech outcomes. The $7.00 eight-analyst average is essentially the consensus midpoint and implies the stock recovers to roughly where it traded in late 2025.
The next two catalysts are the ones that matter. First, REC-4881 in FAP: FDA engagement on a registrational pathway is a meaningful regulatory signal, and the next data update could materially re-rate the equity if the polyp-reduction effect persists. Second, REC-1245 oncology Phase 1 safety has cleared with no dose-limiting toxicities, opening the door to dose-expansion cohorts later in 2026.
For comparable context on AI-discovery and large-cap pharma, the LLY stock price and REGN stock price remain useful reference points for how the market values mature pipelines, while the TEM stock price tracks an adjacent AI-biotech peer also working through the platform-multiple compression. Recursion’s lower absolute valuation reflects its earlier clinical stage rather than a structurally weaker thesis. Patient capital that can withstand another quarter of revenue volatility may find the current zone attractive — but the verdict is balanced, not bullish, and the right framing is to accumulate on weakness rather than chase any single bounce.
RXRX Stock FAQs
Why is RXRX stock dropping?
RXRX is dropping because Q1 2026 revenue fell 56% year-over-year on lumpy milestone timing, momentum signals have flipped negative through the $3.50 break, and the broader AI-biotech basket has re-rated lower as platform multiples compress. The May 7 single-session 4.66% decline took the stock to within $0.47 of its 52-week low.
Is RXRX a buy after the drop?
It depends on time horizon and risk appetite. The 8-analyst consensus is Hold with a $7.00 average target — a balanced view, not a bullish one. With the lowest analyst target ($3.00) below the current $3.27 quote, most of the bear case is already priced. Investors comfortable with clinical-stage biotech volatility may accumulate on weakness ahead of the REC-4881 FAP and REC-1245 oncology readouts.
Will RXRX stock recover?
Recovery depends on three variables: a re-acceleration in partnership milestone revenue, clean data from REC-4881 in FAP supporting the registrational pathway, and dose-expansion progress on REC-1245. The $7.00 average analyst target implies a recovery to late-2025 levels within 12 months; the $11.00 high target requires the broader platform thesis to reassert itself.
What does Recursion Pharmaceuticals do?
Recursion combines robotic wet-lab biology with machine learning to industrialise drug discovery. The company runs proprietary high-throughput phenotypic screens, generates billions of cell-level data points, and uses that dataset to train AI models that nominate and progress drug candidates. Its current clinical pipeline spans oncology, rare disease, and immunology, with partnerships at Roche, Bayer, and Tempus.
What is the RXRX stock price target for 2026?
The 8-analyst 12-month target average is $7.00, with a high of $11.00 and a low of $3.00. A separate 4-analyst panel publishes an $8.00 average with a $10.00 high and a $6.00 low. The bear case is largely already in the price; the bull case requires positive readouts on REC-4881 and REC-1245.
Disclaimer
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Past performance does not guarantee future results. Investors should conduct thorough due diligence and consult qualified financial advisors before making investment decisions.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets. Known for its high liquidity and broad selection of trending tokens, the platform is designed to support both new traders and experienced investors. MEXC also continues to enhance trading efficiency through innovations such as zero trading fees, while prioritizing a secure, user-friendly, and accessible trading experience. Select MEXC as Your 0-fee Gateway To Infinite Opportunities.
